This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Adam Mullick, Ph.D.
Vice President, Cardiovascular Drug Discovery at Ionis Pharmaceuticals

Profile

Dr. Mullick is currently a Vice President of Cardiovascular and Renal Drug Discovery at Ionis Pharmaceuticals. Dr. Mullick contributed to the early development of Kynamro®, WAYLIVRA®, AKCEA-APOCIII-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APO(a)-LRx and led the research efforts for IONIS-AGT-LRx currently in clinical development for treatment-resistant hypertension and heart failure. His current research efforts include preclinical development of targets for heart failure and renal disease in addition to leading the efforts to identify methods to enhance heart oligonucleotide delivery. Dr. Mullick earned his Ph.D. in Molecular, Cellular & Integrative Physiology from UC Davis and was a postdoctoral fellow in the Department of Immunology at The Scripps Research Institute before joining Ionis Pharmaceuticals in 2007.

Agenda Sessions

  • Antisense Oligonucleotide Therapy Targeting Phospholamban Improves Cardiac Function

    5:15pm

Speakers at this event